US 11,999,784 B2
Treatment of peripheral T cell lymphoma
Cécile Bonnafous, Marseilles (FR); Hélène Sicard, Marseilles (FR); Renaud Buffet, Boulogne (FR); and Mathieu Blery, Marseilles (FR)
Assigned to INNATE PHARMA, Marseilles (FR)
Filed by INNATE PHARMA, Marseilles (FR)
Filed on Jun. 25, 2019, as Appl. No. 16/451,051.
Application 16/451,051 is a continuation of application No. 14/767,600, granted, now 10,344,087, previously published as PCT/EP2014/052849, filed on Feb. 13, 2014.
Claims priority of provisional application 61/831,792, filed on Jun. 6, 2013.
Claims priority of provisional application 61/764,639, filed on Feb. 14, 2013.
Prior Publication US 2019/0315857 A1, Oct. 17, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 16/2803 (2013.01); C07K 16/3061 (2013.01); G01N 33/57407 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); G01N 2333/70503 (2013.01)] 1 Claim
 
1. A method for detecting NKp46 expression in an individual having refractory celiac disease (RCD) and treating said individual comprising:
a) obtaining a biological sample from the individual, said biological sample comprising RCD cells, contacting said RCD cells with an antibody that binds NKp46 polypeptide, and detecting NKp46 polypeptide expression on the surface of said cells; and
b) treating individuals expressing NKp46 polypeptide on RCD cells with anti-NKp46 antibodies.